Evidence map›Paper›PMID 41123282›Full record

ArticleProtein science : a publication of the Protein Society2025

AutoRevDock: An open-source toolkit for scalable reverse docking.

Qing Luo, Yuguang Mu, Liangzhen Zheng, Jingjing Guo

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. AutoRevDock: An open-source toolkit for scalable reverse docking.Protein science : a publication of the Protein Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qing LuoCentre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Yuguang MuSchool of Biological Sciences, Nanyang Technological University, Singapore.
Liangzhen ZhengShenzhen Zelixir Biotech Company Ltd., Shenzhen, China.
Jingjing GuoCentre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.ORCID 0000-0002-4632-4364

Funding

Macao Polytechnic University RP/CAI-01/2023Science and Technology Development Fund of Macau (FDCT) 0004/2025/RIA1
6 · The paper itself

Abstract

Reverse docking is a pivotal computational strategy for drug repurposing and polypharmacology studies, yet existing tools often suffer from limitations in throughput, accuracy, and reliance on centralized servers. To overcome these challenges, we present AutoRevDock, an open-source Python toolkit designed to streamline and enhance the reverse docking workflow. Key features include: (1) support for two established docking engines (AutoDock Vina and idock) with a hybrid scoring scheme (Vina_SFCT, combining the Vina score with a scoring function correction term (SFCT)); (2) pre-processed target libraries covering the human proteome and DrugBank pharmacologically active targets; (3) support for custom target libraries and fully automated local execution. Benchmark evaluations demonstrate that idock operates over 40 times faster than AutoDock Vina. For multiple-target drugs, Vina_SFCT outperforms the default scoring function in identifying biologically relevant targets. Furthermore, incorporating protein family information leads to increased hit rates, suggesting enhanced predictive power for real-world applications. By combining robust methodology with user-centric design, AutoRevDock offers a scalable solution for high-throughput target fishing in drug discovery. The toolkit is freely available at https://github.com/AI4Bio-GuoLAB/AutoRevDock.git.

Indexed as

Molecular Docking SimulationProteinsSoftwareDrug RepositioningHumansProteinsdrug repurposingdrug‐target interactionreverse dockingtarget fishingtarget prediction

Identifiers

PMID41123282
PMCPMC12541889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.